Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?

Manoranjenni ChettyMichael Paul DanckwertsAndrea Julsing

Published in: European journal of clinical pharmacology (2020)

The recommended reduction in efavirenz dose from 600 to 400 mg may not provide therapeutic drug levels in EM patients during their T3 of pregnancy, which could lead to therapeutic failure. Clinical trials to evaluate the effectiveness of a 400-mg dose of EFV in T3, especially in EM patients, are needed.

Keyphrases

end stage renal disease
clinical trial
ejection fraction
chronic kidney disease
randomized controlled trial
prognostic factors
systematic review
emergency department
physical activity
open label